Overview

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

Status:
Active, not recruiting

Trial end date:
2021-03-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).

Phase:

Phase 1

Details

Lead Sponsor:

Stemgen

Collaborator:

ORION Clinical Services